… perception de la lumière (MVAC> 3,0 LogMAR) au départ, la population étudiée dans le cadre d' Illuminate était plus … d'acuité visuelle de l'Early Treatment of Diabetic Retinopathy Study (ETDRS ou Étude sur le traitement précoce de la rétinopathie diabétique) et le Test de vision rudimentaire de …
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a biopharmaceutical company dedicated to changing lives through … In addition, ProQR has granted the underwriters a 30-day option to purchase up to 862,500 additional ordinary shares … for the offering. Kempen & Co is acting as the Company’s European financial advisor in relation to this offering. A …
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through … offering, ProQR has granted the underwriters a 30-day option to purchase up to 745,471 additional ordinary shares … as cystic fibrosis, Leber’s congenital amaurosis 10 and dystrophic epidermolysis bullosa. Based on our unique …
… lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today … The 2023 edition of the RNA Editing Summit will focus on optimizing RNA editing technology to safely deliver novel …
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the U.S.